SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cassava Sciences Inc. – ‘8-K’ for 9/14/20

On:  Monday, 9/14/20, at 4:01pm ET   ·   For:  9/14/20   ·   Accession #:  1069530-20-52   ·   File #:  0-29959

Previous ‘8-K’:  ‘8-K’ on / for 9/10/20   ·   Next:  ‘8-K’ on / for 11/4/20   ·   Latest:  ‘8-K’ on / for 4/15/24   ·   1 Reference:  By:  Cassava Sciences Inc. – ‘424B5’ on 11/21/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 9/14/20  Cassava Sciences Inc.             8-K:7,8,9   9/14/20    3:7.3M

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     27K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     55K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     53K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  SAVA 8K Phase 2b Results  

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

FORM 8-K

___________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 14, 2020

___________________

Cassava Sciences, Inc.

(Exact name of registrant as specified in its charter)

___________________

Delaware

 

000-29959

 

91-1911336

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)



7801 N Capital of Texas Highway, Suite 260

Austin, Texas 78731

(Address of principal executive offices, including zip code)

(512) 501-2444

(Registrant’s telephone number, including area code)



Not Applicable

(Former name or former address, if changed since last report.)

___________________



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 



 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))





 Securities registered pursuant to Section 12(b) of the Act:



0

 

 

 

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value

 

SAVA

 

NASDAQ Capital Market





Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 


 

Item 7.01. Regulation FD Disclosure. 



A copy of the Cassava Sciences, Inc. Final Results of a Phase 2b Study of Sumifilam in Alzheimer’s Disease presentation, dated September 14, 2020, is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.



Item 8.01. Other Events.



On September 14, 2020, Cassava Sciences, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference.



Item 9.01 Financial Statements and Exhibits. 





 

 

(d)    Exhibit No.    Description



 

 

99.1

 

Cassava Sciences, Inc. Final Results of a Phase 2b Study of Sumifilam in Alzheimer’s Disease presentation, dated September 14, 2020

99.2

 

Cassava Sciences, Inc. press release dated September 14, 2020



SIGNATURE



Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.





 

 

 

 



CASSAVA SCIENCES, INC.



a Delaware corporation

 

 

 

Date:   September 14, 2020

 

 

 

By:

/s/ ERIC J. SCHOEN

 

 

Eric J. Schoen

 

 

Chief Financial Officer



 



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:9/14/20None on these Dates
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/21/22  Cassava Sciences Inc.             424B5                  2:621K                                   M2 Compliance LLC/FA
Top
Filing Submission 0001069530-20-000052   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., Apr. 17, 11:30:16.1pm ET